



businesswire

A BERKSHIRE HATHAWAY COMPANY

Verndari Announces Breakthrough mRNA Stabilization Discovery

businesswire.com/news/home/20211201005724/en/Verndari-Announces-Breakthrough-mRNA-Stabilization-Discovery

December 1, 2021



SAN DIEGO--(BUSINESS WIRE)--Verndari, Inc., a California-based developer of room-temperature-stable mRNA vaccines, therapeutics and delivery technologies, today announced the discovery of novel formulations that allow cost-effective, room-temperature drying, storage and reconstitution of mRNA with 100% retention of mRNA activity after one month. These patent-pending formulations have the potential for use with all mRNA vaccines, therapeutics and delivery methods.

“We believe this discovery may prove instrumental in helping healthcare leaders overcome the technical, economic and political hurdles that have impeded universal access to COVID-19 vaccines and other life-saving mRNA vaccines and therapeutics.”

“Using a formulation analogous to those of the current, FDA-approved mRNA COVID-19 vaccines, we have been able to dry, store at room temperature, and reconstitute 100% of the activity of the vaccine in vitro,” said Daniel Henderson, CEO and chief scientific officer, Verndari. “We believe this discovery may prove instrumental in helping healthcare leaders overcome the technical, economic and political hurdles that have impeded universal access to COVID-19 vaccines and other life-saving mRNA vaccines and therapeutics.”

Using proprietary formulations, Verndari scientists found that when encapsulated in lipid nanoparticles, dried, stored at room temperature, reconstituted, extracted and analyzed by gel electrophoresis, replicon hemagglutinin mRNA was physically intact after seven days at 25°C. Moreover, when printed on the thermostable Verndari VaxiPatch microarray patch, they found the same formulations to be stable after 28 days at 25°C.

“The ability to stabilize mRNA formulations at room temperature is just the latest in a series of historic scientific advances that are giving hope to people at a time when hope seems most precious,” said Dr. Henderson. “We’re actively engaging in discussions with a range of companies about applying this new technology to dramatically lower distribution costs and open up access to life-saving mRNA vaccines and therapeutics for all people around the world.”

About Verndari

Verndari is a California-based life science company founded in 2015 with the goal of developing and commercializing room-temperature-stable mRNA vaccines, therapeutics and delivery technologies for the protection of all human lives. The company’s patented and patent-pending discoveries are now poised to help healthcare leaders overcome the technical, economic and political hurdles that have impeded universal access to life-saving mRNA vaccines and therapeutics – enabling large-scale, low-cost, global mRNA manufacturing, distribution and administration. More information is available at www.verndariinc.com.